Xanomeline

Xanomeline, as an effective and selective muscarinic type 1 and type 4 (M1/M4) receptor agonist, increases neuronal excitability. Xanomeline can be used for the research of neurological disorders, such as schizophrenia[1][2].

Product Specifications

CAS Number

[131986-45-3]

Product Name Alternative

LY-246708

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/xanomeline.html

Purity

99.95

Solubility

DMSO : 25 mg/mL (ultrasonic) |Ethanol : ≥ 100 mg/mL

Smiles

CCCCCCOC1=NSN=C1C2=CCCN(C)C2

Molecular Formula

C14H23N3OS

Molecular Weight

281.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Kreir M, et al. Role of Kv7.2/Kv7.3 and M1 muscarinic receptors in the regulation of neuronal excitability in hiPSC-derived neurons. Eur J Pharmacol. 2019;858:172474|[2]Shekhar A, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165 (8) :1033-1039.|[3]Andersen MB, et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 2003;28 (6) :1168-1175.